When semaglutide was approved for diabetes, and what that history means for you today

A drug that arrived for diabetes first, and weight loss second

Picture the moment a GP first mentioned Ozempic to a patient with poorly controlled type 2 diabetes in 2019. That was the year the MHRA granted semaglutide its initial UK authorisation, as a once-weekly subcutaneous injection (0.5mg or 1mg) to improve blood-glucose control. At that point, the medicine's effect on body weight was already being noticed in trials, but the weight-management application hadn't been approved yet.

The MHRA licensed Wegovy (semaglutide at the higher 2.4mg weekly maintenance dose) for weight management in 2021. NICE then recommended it for use within specialist NHS weight management services under Technology Appraisal TA875, published in March 2023. The two products share an active ingredient but sit under different licences, different dose schedules and different clinical pathways. That's not a technicality; it shapes every prescribing decision.

More recently, the MHRA approved a dedicated 7.2mg single-dose Wegovy pen on 14 April 2026, extending the weight-management ceiling further still. The Wegovy overview covers the full dose range and what each step involves.

Understanding this timeline helps explain why a GP might have prescribed you Ozempic for diabetes years ago while a separate private clinic offers you Wegovy for weight loss today. They are not the same prescription, even though the molecule is.

What the diabetes licence means if you're now exploring weight management

You've been managing type 2 diabetes for several years, perhaps on Ozempic or another GLP-1 medicine, and your doctor or a weight-management service has raised the possibility of Wegovy. It's a situation our prescribers encounter regularly. The question isn't simply whether semaglutide is right, it's whether Wegovy specifically is right, at this dose, alongside your current diabetes medicines, at this point in your treatment.

The NHS page on semaglutide explains that the weight-management dose is higher than the diabetes dose, which matters for side-effect profile and for interactions with insulin or sulphonylureas (medicines that lower blood sugar). Running both at the same time without prescriber oversight can push blood glucose too low. That's not a reason to rule it out, it's a reason to have the conversation properly.

Our page on Wegovy and type 2 diabetes goes into this in more detail, including what a prescriber typically looks at when both conditions are present. Personal suitability is always a clinical call; broad eligibility rules (BMI thresholds, comorbidities) are starting points, not verdicts.

The things a prescriber weighs (and the things that are still uncertain

Here's what is well established: semaglutide at the weight-management dose produces meaningful average weight reduction in clinical trials) the STEP 1 trial, published in the New England Journal of Medicine, reported roughly 15% average body-weight reduction over 68 weeks in adults without diabetes. Effects in people with type 2 diabetes are documented but typically somewhat lower. What is less certain is how any individual will respond, how their diabetes medicines need adjusting, and whether the timing is right given other health factors.

Pregnancy, breastfeeding and trying to conceive are clear lines: semaglutide is not recommended in any of these situations. If there is any chance of pregnancy, contraception should be in place before starting, and the wash-out period before trying to conceive should be discussed with a doctor. The Wegovy and pregnancy page covers the guidance in full, including whether Wegovy can affect a pregnancy test result.

Surgery is another point worth flagging. If you have a procedure planned, tell the anaesthetist you are taking a GLP-1 medicine, gastric emptying can be affected, which is clinically relevant before general anaesthesia.

Side effects are predominantly gastrointestinal: nausea, loose stools, constipation and indigestion are common when starting or increasing a dose, and usually settle. Severe, persistent stomach pain that spreads to the back is different, that warrants urgent medical attention because of the known, if uncommon, risk of pancreatitis. The MHRA issued a Drug Safety Update on this in January 2026; report any suspected reactions via the Yellow Card scheme.

Getting from here to a prescription, what the private route looks like

If NHS access isn't available to you yet (waiting lists for specialist weight management services remain long, and NICE TA875 criteria are strict), a regulated private pharmacy is the lawful alternative. The route at nume: a free online consultation reviewed by a GPhC-registered Independent Prescriber, a real clinician, reading your answers the same day. Identity and weight are verified; your GP is notified in line with GPhC guidance. If Wegovy is clinically suitable, your order is dispatched the same day you place it before noon on a working day, arriving by DPD the next working day in a plain, unbranded box, you'll get tracking to your phone once it's on its way.

Pricing for private treatment sits separately from the consultation; the Wegovy pricing page explains what one transparent cost covers. If you have questions before starting, the FAQs or our support team are available seven days a week. When you're ready, start your free consultation and a prescriber will take it from there.